January 2022 updates to the website

The website has now been updated following January's LSCMMG

The following guidelines have been added/updated:

Rheumatoid Arthritis High Cost Drugs pathway - updated

Guidelines for the prescribing of nutritional supplements post bariatric surgery - updated

Inclisiran TA 733 position statement - new

The following Items have been updated and added to the website following the latest Strategic Commissioning Committee (SCC) Meeting:

Inclisiran - treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA733)

Upadacitinib - treating moderate rheumatoid arthritis (NICE TA744)

Glycopyrronium oral - hypersalivation in adults and children (non-Parkinson’s disease)

Clonidine 25 mcg tablets - Vasomotor symptoms (VMS) associated with menopause

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Cenobamate - treating focal onset seizures in epilepsy (NICE TA753)

Trixeo Aerosphere - a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist

Bevespi Aerosphere - a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)